Integrated offering to be provided by new dedicated service group under PAREXEL® Access
BOSTON, September 6, 2017 - PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, today announced that it has launched a new end-to-end service offering to provide real-world data insights that help life science companies more effectively demonstrate product value.
“In an increasingly competitive market, leveraging data to demonstrate value is critical. However, unstructured data can make it difficult to overcome gaps in real-world evidence,” said Joshua Schultz, Senior Vice President and Worldwide Head of PAREXEL Access. “Our new service will allow clients to more seamlessly collect and communicate the specific data that payers, physicians, and patients require to establish that a new product offers greater benefits than the existing standard of care.”
PAREXEL’s new offering delivers fit-for-purpose real-world data strategies designed to accelerate market access and mitigate commercial risk. By addressing key factors necessary to demonstrate a product’s value during late-stage development, as well as before and after launch, the offering enables clients to provide high quality evidence that highlights a drug’s unique value.
To deliver this service, PAREXEL has developed a new dedicated real-world data service team with expertise in epidemiology, health economics and outcomes research, market access, analytics, medical sciences, and safety. The group is an expansion of the PAREXEL® Access unit, which provides a complete and simplified solution encompassing evidence-based services throughout the product lifecycle.
The new offering is the latest addition to PAREXEL’s Connected Journey™ of more than 40 data-driven services. The service’s advanced data-aggregation capabilities help assure that clients have access to critical intelligence to inform and support value demonstration. Through these capabilities, primary and secondary data are combined from multiple sources, such as healthcare providers, patient reported outcomes, and electronic data capture, and are leveraged for optimal execution of late-stage programs.
PAREXEL’s real-world data service offering is available worldwide. For more details, please visit: https://www.parexel.com/solutions/access/real-world-evidence/real-world-data-services.
About PAREXEL International
PAREXEL International Corporation is a leading global biopharmaceutical services company, providing a broad range of expertise-based clinical research, consulting, medical communications, and technology solutions and services to the worldwide pharmaceutical, biotechnology, and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, and reimbursement. PAREXEL Informatics provides advanced technology solutions, including medical imaging, to facilitate the integrated clinical development and regulatory information management process. Headquartered near Boston, Massachusetts, PAREXEL has offices in 85 locations in 52 countries around the world, and had approximately 18,900 employees at the end of the fourth quarter. For more information about PAREXEL International visit www.PAREXEL.com.
PAREXEL and PAREXEL Informatics are trademarks or registered trademarks of PAREXEL International Corporation or its affiliates. All other trademarks are the property of their respective owners.
This release contains “forward-looking” statements regarding future results and events. For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words “believes,” “anticipates,” “plans,” “expects,” “intends,” “appears,” “estimates,” “projects,” “will,” “would,” “could,” “should,” “targets,” and similar expressions are also intended to identify forward-looking statements. The forward-looking statements in this release involve a number of risks and uncertainties. Such factors and others are discussed in the section entitled “Risk Factors” of the Company’s most recent Annual Report on Form 10-K and subsequent quarterly reports on Form 10-Q filed with the Securities and Exchange Commission, which “Risk Factors” discussion is incorporated by reference in this press release. The Company specifically disclaims any obligation to update these forward-looking statements in the future. These forward-looking statements should not be relied upon as representing the Company’s estimates or views as of any date subsequent to the date of this press release.
# # #
Tel.: +1 781-434-4772
Jenny Radloff, PAN Communications
Tel.: +1 617-502-4300
Tel.: +1 781-434-4753